Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.

PLoS One · 2017 · PMC5519037 · PMID 28727815

Europe PMC DOI

hedged sentence

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

showed a trendP = 0.056so close (0.05 < p ≤ 0.1)

The analysis of time to treatment modification due to toxicity showed a trend (HR = 0.58, 95%CI = 0.33–1.01, P = 0.056) for FGFR4 rs351855 under an additive genetic model ( Table 3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.